Advertisement

Archives of Pharmacal Research

, Volume 30, Issue 4, pp 519–525 | Cite as

Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles

  • Qing-yu Xiang
  • Min-ting Wang
  • Fu Chen
  • Tao Gong
  • Yan-lin Jian
  • Zhi-rong Zhang
  • Yuan HuangEmail author
Article

Abstract

The objective of the present study was to develop a novel solid lipid nanoparticle (SLN) for the lung-targeting delivery of dexamethasone acetate (DXM) by intravenous administration. DXM loaded SLN colloidal suspensions were prepared by the high pressure homogenization method. The mean particle size, drug loading capacity and drug entrapment efficiency (EE %) of SLNs were investigated. In vitro drug release was also determined. The biodistribution and lung-targeting efficiency of DXM-SLNs and DXM-solutions (DXM-sol) in mice after intravenous administration were studied using reversed-phase high-performance liquid chromatography (HPLC). The results (expressed as mean ± SD) showed that the DXM-SLNs had an average diameter of 552 ± 6.5 nm with a drug loading capacity of 8.79 ± 0.04% and an entrapment efficiency of 92.1 ± 0.41%. The in vitro drug release profile showed that the initial burst release of DXM from DXM-SLNs was about 68% during the first 2 h, and then the remaining drug was released gradually over the following 48 hours. The biodistribution of DXM-SLNs in mice was significantly different from that of DXM-sol. The concentration of DXM in the lung reached a maximum level at 0.5 h post DXM-SLNs injection. A 17.8-fold larger area under the curve of DXM-SLNs was achieved compared to that of DXM-sol. These results indicate that SLN may be promising lung-targeting drug carrier for lipophilic drugs such as DXM.

Key words

Dexamethasone acetate Solid lipid nanoparticles Lung-targeting 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chinese Pharmacopoeia, pp. 184 (2005).Google Scholar
  2. Dik, W. A., McAnulty, R. J., Versnel, M. A., Naber, B. A., Zimmermann, L. J., Laurent, G. J., and Mutsaers, S. E., Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats.Thorax, 58, 765–71 (2003).PubMedCrossRefGoogle Scholar
  3. Darwis, Y. and Kellaway, I. W., Nebulization of rehydrated freeze-dried beclomethasone dipropionate liposomes.Int. J. Pharm., 215, 113–121 (2001).PubMedCrossRefGoogle Scholar
  4. Eldem, T., Speiser, P., and Hincal, A., Optimization of spray- dried and -congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy.Pharm. Res., 8, 47–54 (1991).PubMedCrossRefGoogle Scholar
  5. Fundaro, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., and Gasco, M. R., Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution afteri.v. administration to rats.Pharm. Res., 42, 337–343 (2000).CrossRefGoogle Scholar
  6. Gert, S., Sheila, O. B., Toos, D., and Danilo, D. L., Surface modification of nanoparticles to oppose uptake by the mononudear phagocyte system.Adv. Drug Deliv. Rev., 17, 31–48 (1995).CrossRefGoogle Scholar
  7. Groeneveld, A. B., Vascular pharmacology of acute lung injury and acute respiratory distress syndrome.Vasc. Pharmacol., 39, 247–256 (2002).CrossRefGoogle Scholar
  8. Huo, D. J., Deng, S. H., Li, L. B., and Ji, J., Studies on the poly(lactic-co-glycolic) acid microspheres of cisplatin for lungtargeting. Inf.J. Pharm., 289, 63–67 (2005).Google Scholar
  9. Jenning, V., Mader, K., and Gohla, S. H., Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: a (1)H-NMR study.Int. J. Pharm., 205, 15–21 (2000).PubMedCrossRefGoogle Scholar
  10. Joshi, M. and Misra, A., Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung.Clin. Exp. Pharmacol P., 30, 153–156 (2003).CrossRefGoogle Scholar
  11. Kellaway, I. W. and Farr, S. J., Liposomes as drug delivery systems to the lung.Adv. Drug Deliv. Rev., 5, 149–161 (1990).CrossRefGoogle Scholar
  12. Li, H. P., Li, X., He, G. J., Yi, X. H., and Kaplan, A. P., The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycininduced pulmonary fibrosis in rats.Respirology, 9, 25–32 (2004).PubMedCrossRefGoogle Scholar
  13. Lukowski, G. and Pflegel, P., Electron diffraction of solid lipid nanoparticles loaded with aciclovir.Pharmazie, 52, 642–643 (1997).Google Scholar
  14. Mehnert, W. and Mader, K., Solid lipid nanoparticles: production, characterization and applications.Adv. Drug Deliv. Rev., 47, 165–196 (2001).PubMedCrossRefGoogle Scholar
  15. Moghimi, S. M., Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers.Adv. Drug Deliv. Rev., 16, 183–193 (1995).CrossRefGoogle Scholar
  16. Müller, R. H., Karsten, M., and Sven, G., Solid lipid nanoparticles (SLN) for controlled drug delivery-α review of the state of the art.Eur. J. Pharm. Biopharm., 50, 161–177 (2000).PubMedCrossRefGoogle Scholar
  17. Müller, R.H., Maaseen, S., Schwarz, C., and Mehnert, W., Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes.J. Control. Release, 47, 261–269 (1997).CrossRefGoogle Scholar
  18. Mühlen, zur A. and Mehnert, W., Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles.Pharmazie, 53, 552 (1998).Google Scholar
  19. Ozkan, Y., Dikmen, N., Isimer, A., Gunhan, O., and Aboul-Enein, H. Y., Clarithromycin targeting to lung: characterization, size distribution andin vivo evaluation of the human serum albumin microspheres.Farmaco, 55, 303–307 (2000).PubMedCrossRefGoogle Scholar
  20. Serpe, L., Catalano, M. G., Cavalli, R., Ugazio, E., Bosco, O., Canaparoa, R., Muntoni, E., Frairia, R., Gasco, M. R., Eandi, M., and Zara, G. P., Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line.Eur. J. Pharm. Biopharm., 58, 673–680 (2004).PubMedCrossRefGoogle Scholar
  21. Serrano, A. G. and Perez-Gil, J., Protein-lipid interactions and surface activity in the pulmonary surfactant system.Chem. Phys. Lipids, 141, 105–118 (2006).PubMedCrossRefGoogle Scholar
  22. Siekmann, B. and Westesen, K., Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. I. Preparation and particle size determination.Pharm. Pharmacol. Lett., 3, 194–197 (1994).Google Scholar
  23. Speiser, P., Lipidnanopellets als Tragersystem fur Arzneimittel zur peroralen Anwendung. European Patent EP0167825 (1990).Google Scholar
  24. Suzuki, S., Kawakami, S., Chansri, N., Yamashita, F., and Hashida, M., Inhibition of pulmonary metastasis in mice by all-trans retinoic acid incorporated in cationic liposomes.J. Control. Release, 116, 58–63 (2006).PubMedCrossRefGoogle Scholar
  25. Swigris, J. J, Kuschner, W. G., Kelsey, J. L., and Gould, M. K., Idiopathic pulmonary fibrosis: challenges and opportunities for the clinician and investigator.Chest, 127, 275–283 (2005).PubMedCrossRefGoogle Scholar
  26. Tao, Z. W., Xu, Q. Y., Ye, Y. Q., Peng, P., and Wang, Z. R., Preparation andin vitro characterization of microspheres containing dexamethasone sodium phosphate.Chin. Hosp. Pharm. J., 26, 515–517 (2006).Google Scholar
  27. Wang, J. S., Zhu, J. B., Lu, R. Q., and Shen, W., Preparation of lung targeting azithromycin liposomes and its tissue distribution in mice.Acta Pharm. Sin., 40, 274–278 (2005).Google Scholar
  28. Wang, J. X., Sun, X., and Zhang, Z. R., Enhanced brain targeting by synthesis of 3′, 5′-dioctanoyl- 5-fluoro- 2′- deoxyuridine and incorporation into solid lipid nanoparticles.Eur. J. Pharm. Biopharm., 54, 285–290 (2002).PubMedCrossRefGoogle Scholar
  29. Wolfgang, M. and Karsten, M., Solid lipid nanoparticles Production, characterization and applications.Adv. Drug Deliv. Rev., 47, 165–196 (2001).CrossRefGoogle Scholar
  30. Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., and Yang, C. Z., Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain.J. Control. Release, 59, 299–307 (1999).PubMedCrossRefGoogle Scholar
  31. Zara, G. P., Cavalli, R., Fundaro, A., Bargoni, A., Caputo, O., and Gasco, M. R., Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN).Pharm. Res., 40, 281–286 (1999).CrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2007

Authors and Affiliations

  • Qing-yu Xiang
    • 1
  • Min-ting Wang
    • 1
  • Fu Chen
    • 1
  • Tao Gong
    • 1
  • Yan-lin Jian
    • 1
  • Zhi-rong Zhang
    • 1
  • Yuan Huang
    • 1
    Email author
  1. 1.Key Laboratory of Drug Targeting of Ministry of EducationWest China School of Pharmacy, Sichuan UniversityChengduP.R. China

Personalised recommendations